|
Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. |
|
|
|
Stock and Other Ownership Interests - PD-value |
Consulting or Advisory Role - Aduro Biotech |
|
|
Employment - Aduro Biotech |
|
|
Employment - Aduro Biotech |
Travel, Accommodations, Expenses - Aduro Biotech |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
Patents, Royalties, Other Intellectual Property - Stanford University School of Medicine |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Juno Therapeutics; Novartis; Sanofi; Spectrum Pharmaceuticals |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Kite, a Gilead company; Sanofi; Spectrum Pharmaceuticals; Takeda |
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst) |
|
|
Honoraria - Acetylon Pharmaceuticals; Amgen; Celgene |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Merck; Sanofi |
Speakers' Bureau - Amgen; Celgene; Takeda |
Research Funding - Acetylon Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celgene; Karyopharm Therapeutics; Merck; Sanofi |
Expert Testimony - Celgene; Takeda |